



**ESSEX BIO-TECHNOLOGY LIMITED**  
**億勝生物科技有限公司**

**Press Release**

**GROUP PHARMACEUTICAL BUSINESS RECORDED GROWTH OF  
22.6% & 38.3% IN TURNOVER AND PROFIT RESPECTIVELY**

\*\*\*

Hong Kong, 11 August 2010 - - ESSEX BIO-TECHNOLOGY LIMITED (“Essex” or the “Group” - Stock Code: 8151) today announced that the Group recorded approximately HK\$61.2 million in turnover for the six months ended 30 June 2010, an increase of 22.6% over the corresponding previous period.

Overall gross profit for the six months ended 30 June 2010 increased to approximately HK\$55.7 million when compared to approximately HK\$44.8 million recorded in the same period of last year. Profit attributable to owners of the company increased by 38.3% to approximately HK\$11.2 million as compared to approximately HK\$4.7 million in the corresponding previous period.

Distribution and selling expenses increased to approximately HK\$36.5 million for the six months ended 30 June 2010 when compared to approximately HK\$28.7 million recorded in the same period of last year. The increase was mainly attributable to higher expenses incurred in sales, marketing and promotional activities which are in line with the growth of pharmaceutical business in the period under review.

Administration expenses slightly increased to approximately HK\$6.3 million for the six months ended 30 June 2010 as compared to approximately HK\$6.0 million in the corresponding previous period.

The Group had cash and cash equivalents of approximately HK\$68.4 million as at 30 June 2010 (31 December 2009: HK\$67.7 million).

As at 30 June 2010 and 31 December 2009, the Group has no bank and other borrowings.

During the period under review, the Group established 3 more direct representative offices (“DROs”) in Shanghai, Jilin and Lanzhou, bringing the total number of DROs to 23. The DROs are located in major provinces in the PRC. There are over 1,300 hospitals in major provinces in the PRC that carry the Group’s flagship pharmaceutical products.

*Chairman Patrick Ngiam said, “Having consecutively achieved quarter to quarter growth both in top and bottom lines, the Group has gained further strength for its products in the market place. Together with it's strong cash position, the Group is well poised for growth and investment opportunities.”*

**About Essex Bio-Technology Limited:**

Essex Bio-Technology Limited (“Essex”) was listed on the Growth Enterprise Market (GEM) of The Stock Exchange of Hong Kong Limited on 27 June 2001, under stock code (8151).

Essex specializes in biopharmaceutical drug development based on recombinant DNA technology. It is principally engaged in the manufacture and sale of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds and the research and development of biopharmaceutical products for the treatment of duodenal ulcers and nervous system damages and diseases, as well as other ophthalmic pharmaceutical projects.

*For more information, please contact:*

**Essex Bio-Technology Limited**

Email : [essex@essexbio.com](mailto:essex@essexbio.com)

Tel : (852) 2587-7838

Fax : (852) 2587-7363

**Summary of key information:**

	<b>For the six months ended 30 June 2010 HK\$'m</b>
<u>Continuing Operations</u>	
Turnover	61.2
Gross profit	
- in HK\$'m	55.7
Profit attributable to owners of the Company	11.2
<u>Earnings per share – basic</u>	
Continuing and discontinued operations	HK2.02 cents
Continuing operations	HK2.02 cents
Dividend	Nil
	<b>As at 30 June 2010 HK\$'m</b>
Cash and cash equivalents	68.4
Bank borrowings	Nil

- End -